I-cell disease (mucolipidosis II)

Lysosomes are the parts of a cell that break down and recycle used material, using many different digestive enzymes. Newly made enzymes get a chemical “address tag” that sends them to the lysosomes. In mucolipidosis II, the tagging step does not work, so many enzymes leak out of the cell instead. Material then builds up inside the lysosomes.

The name I-cell disease comes from “inclusion cells,” which look packed with stored material under a microscope. Mucolipidosis II is the severe end of a range of conditions caused by the same gene. The milder end is called mucolipidosis III, and some children fall in between.

Doctors suspect it from signs at birth and bone changes on x-rays. Blood tests can show that several lysosomal enzymes are far higher than usual, because they have leaked out of cells. Genetic testing confirms the diagnosis.

Mucolipidosis II is caused by changes in both copies of the GNPTAB gene. This gene holds the instructions for part of the enzyme that adds the address tag to other enzymes. In mucolipidosis II, the gene changes leave no working tagging enzyme.

It is inherited in an autosomal recessive pattern. Each parent usually carries one changed copy and has no symptoms. When both parents are carriers, each child has a 1 in 4 chance of being affected.

It is not caused by anything a parent did during pregnancy, and it is not contagious. Once the family’s gene changes are known, carrier testing for relatives and testing in future pregnancies are possible. A genetic counselor can explain the options.

Babies are often small at birth, with weak muscle tone and bone differences such as clubfeet, dislocated hips, a rounded upper back and unusually shaped long bones. Growth usually stops during the second year of life. The joints become stiff, and most children do not learn to walk on their own.

Every child with mucolipidosis II has heart involvement, most often a thick, leaky mitral valve. The airways slowly narrow and the chest becomes stiff, which makes breathing harder and chest infections more serious. Other features include thick skin, coarse facial features, overgrown gums, a hoarse voice, hernias, ear infections and hearing loss. Development, especially speech and movement, is delayed.

Breathing failure is the most common cause of death, and most children with this condition do not survive past early childhood.

Families often face many hospital visits in the first months and years. Regular checks of the bones, heart, lungs, growth, hearing and development help the care team spot problems early. Chest infections can become serious quickly.

Caring for a child with complex medical needs affects the whole family. Social work and family support are part of good care. Palliative care teams focus on comfort and quality of life, and they can work alongside other treatment.

Families who connect with others living with the same rare condition often find understanding and practical tips that are hard to get elsewhere.

Transplant is not routine care for mucolipidosis II. Where it has been tried, the cells came from another person. Published cases have used family donors, unrelated volunteers and umbilical cord blood.

A shortage of registry donors is not what holds back care for this condition. Donor cells have not been shown to fix its main problems, so new kinds of treatment are the bigger need.

Joining a registry still matters. It helps the many patients with other conditions for whom an unrelated donor transplant is an established treatment.